Teitl: A prospective, observational study to evaluate quality of life, patient reported outcomes, and safety in patients with relapsing-remitting Multiple Sclerosis who are being treated with Alemtuzumab (Lemtrada) in routine clinical practice
Arianwyr
Sanofi
Prif Ymchwiliwr
Manylion y Prosiect
Gwerth net y ffigur a ddyfarnwyd i Brifysgol Caerdydd: £1,456.00
Dyddiad dechrau: 22.12.2016
Dyddiad gorffen: 31.12.2019